Latest News
BioStock’s article series on autoimmune disease: Drug Development for RA and MS
BioStock published an article on 4 July 2019 about autoimmune diseases, which can be read in full below. Therapies for autoimmune diseases are available but do not work for all patients, and when they do, side effects can be...
Read MoreArticle in BioStock: World MS Day: Cyxone aims to deliver better, safer treatments to multiple sclerosis patients
BioStock published an article about Cyxone on 29 May 2019, which can be read below. As mainstream MS treatments get scolded by the FDA and the EMA after reports from patients experiencing severe side effects, the market for safer,...
Read MorePharmaceutical Business Review: Cyxone MS drug T20K succeeds in preclinical program
Cyxone MS drug T20K succeeds in preclinical program Cyxone said that T20K, its investigational drug for the treatment of multiple sclerosis (MS), has succeeded in a preclinical program by yielding positive results in the toxicology studies. According to Cyxone,...
Read MoreMedUni Vienna technology wins Recognition Prize in the science2business awards
A joint project between MedUni Vienna and Freiburg University Hospital, using cyclotides as a treatment for multiple sclerosis, was awarded the Recognition Prize in the science2business awards. This development is an example of a successful transfer of innovation from...
Read MoreMultiple sclerosis: plant peptide could prevent onset of the disease
MedUni Vienna has made a crucial development in the treatment of Multiple Sclerosis (MS): Together with his team and the research group led by Gernot Schabbauer, international partners from Australia, Germany and Sweden, Christian Gruber, Chief Researcher at the...
Read MoreSuccessful IPO with MedUni Vienna patent
Swedish company Cyxone, a subsidiary of ACCEQUA AB, headquartered in Malmö, recently went public – on the basis of a MedUni Vienna patent application relating to the potential development of an oral medication to combat multiple sclerosis. The invention...
Read MoreMultiple sclerosis: Plant peptide could prevent onset of the disease
https://www.sciencedaily.com/releases/2016/03/160329101244.htm
Read MoreOral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis
http://www.pnas.org/content/113/15/3960.full
Read MoreOral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis
http://www.pnas.org/content/early/2016/03/22/1519960113.full.pdf http://tvthek.orf.at/program/ZIB-1/1203/ZIB-1/12317916/Hoffnung-fuer-Multiple-Sklerose-Patienten/12318077
Read More